These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33966455)

  • 1. Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells.
    Kowalski J; Deng L; Suennen C; Koca D; Meral D; Bode C; Hein L; Lother A
    Hypertension; 2021 Aug; 78(2):456-465. PubMed ID: 33966455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonism improves parenchymal arteriole dilation via a TRPV4-dependent mechanism and prevents cognitive dysfunction in hypertension.
    Diaz-Otero JM; Yen TC; Fisher C; Bota D; Jackson WF; Dorrance AM
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1304-H1315. PubMed ID: 30118343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.
    Hashimoto A; Takeda Y; Karashima S; Kometani M; Aono D; Demura M; Higashitani T; Konishi S; Yoneda T; Takeda Y
    Hypertens Res; 2020 Oct; 43(10):1099-1104. PubMed ID: 32398797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.
    Boehm M; Arnold N; Braithwaite A; Pickworth J; Lu C; Novoyatleva T; Kiely DG; Grimminger F; Ghofrani HA; Weissmann N; Seeger W; Lawrie A; Schermuly RT; Kojonazarov B
    BMC Pulm Med; 2018 Mar; 18(1):41. PubMed ID: 29499691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
    Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
    Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of myogenic tone and structure of parenchymal arterioles by hypertension and the mineralocorticoid receptor.
    Pires PW; Jackson WF; Dorrance AM
    Am J Physiol Heart Circ Physiol; 2015 Jul; 309(1):H127-36. PubMed ID: 25910805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone-induced degradation of the TFIIH core complex XPB subunit suppresses NF-κB and AP-1 signalling.
    Elinoff JM; Chen LY; Dougherty EJ; Awad KS; Wang S; Biancotto A; Siddiqui AH; Weir NA; Cai R; Sun J; Preston IR; Solomon MA; Danner RL
    Cardiovasc Res; 2018 Jan; 114(1):65-76. PubMed ID: 29036418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
    Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonists and endothelial function.
    Maron BA; Leopold JA
    Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
    McMahon EG
    Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension.
    Maron BA; Zhang YY; White K; Chan SY; Handy DE; Mahoney CE; Loscalzo J; Leopold JA
    Circulation; 2012 Aug; 126(8):963-74. PubMed ID: 22787113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity.
    Hullin R; Métrich M; Sarre A; Basquin D; Maillard M; Regamey J; Martin D
    Cardiovasc Res; 2018 Feb; 114(2):272-281. PubMed ID: 29016737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
    Preston IR; Sagliani KD; Warburton RR; Hill NS; Fanburg BL; Jaffe IZ
    Am J Physiol Lung Cell Mol Physiol; 2013 May; 304(10):L678-88. PubMed ID: 23457185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell mineralocorticoid receptor.
    Dinh QN; Young MJ; Evans MA; Drummond GR; Sobey CG; Chrissobolis S
    Brain Res; 2016 Apr; 1637():146-153. PubMed ID: 26923165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
    George J; Struthers AD
    Expert Opin Pharmacother; 2007 Dec; 8(17):3053-9. PubMed ID: 18001264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity.
    Lother A; Bergemann S; Kowalski J; Huck M; Gilsbach R; Bode C; Hein L
    Cardiovasc Res; 2018 Feb; 114(2):282-290. PubMed ID: 28430882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension.
    Fujimura N; Noma K; Hata T; Soga J; Hidaka T; Idei N; Fujii Y; Mikami S; Maruhashi T; Iwamoto Y; Kihara Y; Chayama K; Kato H; Liao JK; Higashi Y;
    Clin Pharmacol Ther; 2012 Feb; 91(2):289-97. PubMed ID: 22205191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
    Arai K; Tsuruoka H; Homma T
    Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
    Nakamura T; Fukuda M; Kataoka K; Nako H; Tokutomi Y; Dong YF; Yamamoto E; Yasuda O; Ogawa H; Kim-Mitsuyama S
    Hypertens Res; 2011 Jul; 34(7):817-24. PubMed ID: 21471977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined CaMKII inhibition and mineralocorticoid receptor antagonism via eplerenone inhibits functional deterioration in chronic pressure overloaded mice.
    Driessen HE; Fontes MS; van Stuijvenberg L; Brans MA; Goumans MJ; Vos MA; van Veen TA
    J Cell Mol Med; 2020 Aug; 24(15):8417-8429. PubMed ID: 32573944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.